VETAMIX®
A Division of LLOYD, Inc.

85

For Veterinary Use Only

ClindaRobe™ Capsules

(clindamycin hydrochloride)

361-33-702464600 Rev. 01

For Veterinary Use Only

ClindaRobe™ Capsules
(clindamycin hydrochloride)

Caution
Federal law restricts this drug to use by or on the order of a licensed veterinarian.

DESCRIPTION

ClindaRobe™ Capsules contain clindamycin hydrochloride which is the hydrated salt of clindamycin. Clindamycin is a semi-synthetic antibiotic produced by a 7(S)-chloro-substitution of the 7(R)-hydroxyl group of a naturally produced antibiotic produced by *Streptomyces lincolnensis* var. lincolnensis.

ClindaRobe™ Capsules (For Use in Dogs Only):
25mg Capsule – Each opaque white body and opaque yellow cap, size#3 hard gelatin capsules; imprinted in black ink nv and 25 on opposing cap and body portions of the capsule contains clindamycin hydrochloride equivalent to 25 mg of clindamycin.

75mg Capsule – Each opaque white body and opaque dark green cap, size#3 hard gelatin capsules; imprinted in black ink nv and 75 on opposing cap and body portions of the capsule contains clindamycin hydrochloride equivalent to 75 mg of clindamycin.

150mg Capsule – Each opaque maroon cap and opaque amethyst body, size#1 hard gelatin capsules; printed in white ink N and 150 on opposing cap and body portions of the capsule contains clindamycin hydrochloride equivalent to 150 mg of clindamycin.

ACTIONS

Site and Mode of Action: Clindamycin is an inhibitor of protein synthesis in the bacterial cell. The site of binding appears to be in the 50S sub-unit of the ribosome. Binding occurs to the soluble RNA fraction of certain ribosomes, thereby inhibiting the binding of amino acids to those ribosomes. Clindamycin differs from cell wall inhibitors in that it causes irreversible modification of the protein-synthesizing subcellular elements at the ribosomal level.

Microbiology: Clindamycin is a lincosaminide antimicrobial agent with activity against a wide variety of aerobic and anaerobic bacterial pathogens. Clindamycin is a bacteriostatic compound that inhibits bacterial protein synthesis by binding to the 50S ribosomal sub-unit. The minimum inhibitory concentrations (MICs) of Gram-positive and obligate anaerobic pathogens isolated from dogs in the United States are presented in Table 1. Bacteria were isolated in 1998-1999. All MICs were performed in accordance with the National Committee for Clinical Laboratory Standards (NCCLS).

Table 1. Clindamycin MIC Values (µg/mL) from Diagnostic Laboratory Survey Data Evaluating Canine Pathogens in the U.S. During 1998-99[1]

Organism	Number of Isolates	MIC_{50}	MIC_{85}	MIC_{90}	Range
Soft Tissue/Wound[2]					
Staphylococcus aureus	17	0.5	0.5	≥4.0	0.25-≥4.0
Staphylococcus intermedius	28	0.25	0.5	≥4.0	0.125-≥4.0
Staphylococcusspp.	18	0.5	0.5	≥4.0	0.25-≥4.0
Beta-hemolytic streptococci	46	0.5	0.5	≥4.0	0.25-≥4.0
Streptococcusspp.	11	0.5	≥4.0	≥4.0	0.25-≥4.0
Osteomyelitis/Bone[3]					
Staphylococcus aureus	20	0.5	0.5	0.5	0.5[4]
Staphylococcus intermedius	15	0.5	≥4.0	≥4.0	0.25-≥4.0
Staphylococcusspp.	18	0.5	≥4.0	≥4.0	0.25-≥4.0
Beta-hemolytic streptococci	21	0.5	2.0	2.0	0.25-≥4.0
Streptococcusspp.	21	≥4.0	≥4.0	≥4.0	0.25-≥4.0

(continued)

Table 1. Clindamycin MIC Values (µg/mL) from Diagnostic Laboratory Survey Data Evaluating Canine Pathogens in the U.S. During 1998-99[1]

Organism	Number of Isolates	MIC_{50}	MIC_{85}	MIC_{90}	Range
Dermal/Skins[5]					
Staphylococcus aureus	25	0.5	≥4.0	≥4.0	0.25-≥4.0
Staphylococcus intermedius	48	0.5	≥4.0	≥4.0	0.125-≥4.0
Staphylococcusspp.	32	0.5	≥4.0	≥4.0	0.25-≥4.0
Beta-hemolytic streptococci	17	0.5	0.5	0.5	0.25-≥0.5

[1] The correlation between these in vitro susceptibility data and clinical response has not been determined.
[2] Soft Tissue/Wound: includes samples labeled wound, abscess, aspirate, exudates, draining tract, lesion, and mass
[3] Osteomyelitis/Bone: includes samples labeled bone, fracture, joint, tendon
[4] No range, all isolates yielded the same value
[5] Dermal/Skin: includes samples labeled skin, skin swab, biopsy, incision, lip

PHARMACOLOGY

Absorption: Clindamycin hydrochloride is rapidly absorbed from the canine gastrointestinal tract.

Dog Serum Levels: Serum levels at or above 0.5 µg/mL can be maintained by oral dosing at a rate of 2.5 mg/lb of clindamycin hydrochloride every 12 hours. This same study revealed that average peak serum concentrations of clindamycin occur 1 hour and 15 minutes after oral dosing. The elimination half-life for clindamycin in dog serum was approximately 5 hours. There was no bioactivity accumulation after a regimen of multiple oral doses in healthy dogs.

Clindamycin Serum Concentrations 2.5 mg/lb (5.5 mg/kg)
After B.I.D. Oral Dose of clindamycin hydrochloride capsules to Dogs



METABOLISM AND EXCRETION

Extensive studies of the metabolism and excretion of clindamycin hydrochloride administered orally in animals and humans have shown that unchanged drug and bioactive and bioinactive metabolites are excreted in urine and feces. Almost all of the bioactivity detected in serum after clindamycin hydrochloride product administration is due to the parent molecule (clindamycin). Urine bioactivity, however, reflects a mixture of clindamycin and active metabolites, especially N-demethyl clindamycin and clindamycin sulfoxide.

ANIMAL SAFETY SUMMARY
Rat and Dog Data: One year oral toxicity studies in rats and dogs at doses of 30, 100 and 300 mg/kg/day (13.6, 45.5 and 136.4 mg/lb/day) have shown clindamycin hydrochloride to be well tolerated. Differences did not occur in the parameters evaluated to assess toxicity when comparing groups of treated animals with contemporary controls. Rats administered clindamycin hydrochloride at 600 mg/kg/day (272.7 mg/lb/day) for six months tolerated the drug well; however, dogs orally dosed at 600 mg/kg/day (272.7 mg/lb/day) vomited, had anorexia, and subsequently lost weight. At necropsy these dogs had erosive gastritis and focal areas of necrosis of the mucosa of the gallbladder.

Safety in gestating bitches or breeding males has not been established.

INDICATIONS
ClindaRobe™ Capsules (for use in dogs only) is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below:

Dogs: Skin infections (wounds and abscesses) due to coagulase positive staphylococci (*Staphylococcus aureus* or *Staphylococcus intermedius*). Deep wounds and abscesses due to *Bacteroides fragilis*, *Prevotella melaninogenicus*, *Fusobacterium necrophorum* and *Clostridium perfringens*. Dental infections due to *Staphylococcus aureus*, *Bacteroides fragilis*, *Prevotella melaninogenicus*, *Fusobacterium necrophorum* and *Clostridium perfringens*. Osteomyelitis due to *Staphylococcus aureus*, *Bacteroides fragilis*, *Prevotella melaninogenicus*, *Fusobacterium necrophorum* and *Clostridium perfringens*.

CONTRAINDICATIONS
ClindaRobe™ Capsules are contraindicated in animals with a history of hypersensitivity to preparations containing clindamycin or lincomycin.

Because of potential adverse gastrointestinal effects, do not administer to rabbits, hamsters, guinea pigs, horses, chinchillas or ruminating animals.

WARNINGS
Keep out of reach of children. Not for human use.

PRECAUTIONS
During prolonged therapy of one month or greater, periodic liver and kidney function tests and blood counts should be performed.

The use of clindamycin hydrochloride occasionally results in overgrowth of non-susceptible organisms such as clostridia and yeasts. Therefore, the administration of ClindaRobe™ Capsules should be avoided in those species sensitive to the gastrointestinal effects of clindamycin (see CONTRAINDICATIONS). Should superinfections occur, appropriate measures should be taken as indicated by the clinical situation.

Patients with very severe renal disease and/or very severe hepatic disease accompanied by severe metabolic aberrations should be dosed with caution, and serum clindamycin levels monitored during high-dose therapy.

Clindamycin hydrochloride has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. Therefore, clindamycin hydrochloride should be used with caution in animals receiving such agents.

Safety in gestating bitches or breeding male dogs has not been established.

ADVERSE REACTIONS
Side effects occasionally observed in either clinical trials or during clinical use were vomiting and diarrhea.

To report adverse reactions or a suspected adverse reaction call 1-800-831-0004.

DOSAGE AND ADMINISTRATION
Dogs:
Infected Wounds, Abscesses and Dental Infections
Oral: 2.5-15.0 mg/lb body weight every 12 hours.

Duration: Treatment with ClindaRobe™ Capsules may be continued up to a maximum of 28 days if clinical judgment indicates. Treatment of acute infections should not be continued for more than three or four days if no response to therapy is seen.

Dosage Schedule:
ClindaRobe™ Capsules 25 mg, administer 1-6 capsules every 12 hours for each 10 pounds of body weight.

ClindaRobe™ Capsules 75 mg, administer 1-6 capsules every 12 hours for each 30 pounds of body weight.

ClindaRobe™ Capsules 150 mg, administer 1-6 capsules every 12 hours for each 60 pounds of body weight.

Osteomyelitis
Oral: 5.0-15.0 mg/lb body weight every 12 hours.

Duration: Treatment with ClindaRobe™ Capsules is recommended for a minimum of 28 days. Treatment should not be continued for longer than 28 days if no response to therapy is seen.

Dosage Schedule:
ClindaRobe™ Capsules 25 mg, administer 2-6 capsules every 12 hours for each 10 pounds of body weight.

ClindaRobe™ Capsules 75 mg, administer 2-6 capsules every 12 hours for each 30 pounds of body weight.

ClindaRobe™ Capsules 150 mg, administer 2-6 capsules every 12 hours for each 60 pounds of body weight.

HOW SUPPLIED
ClindaRobe™ Capsules are supplied as:

25 mg – bottles of 200	NDC 65163-074-53
bottles of 600	NDC 65163-074-74
75 mg – bottles of 200	NDC 65163-075-53
150 mg – bottles of 100	NDC 65163-076-40

ANADA # 200-383, approved by FDA

To report a suspected adverse reaction or to request a material safety data sheet (MSDS), call 1-800-831-0004.

Store at controlled room temperature 20° to 25° C (66° to 77° F) [See USP].

Made in Canada for
Vet-A-Mix, A Division of Lloyd Inc,
Shenandoah, Iowa 51601
by Novopharm Limited
30 Novopharm Court
Toronto, Canada M1B 2K9

0305

Revised January 2008
361-33-702464600 Rev. 01